Man Group’s Cytek Biosciences CTKB Stock Holding History

Man Group’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-13,700	Closed	-$110K	–	1545
2023 Q2	$117K	Buy	+13,700	New	+$123K	﹤0.01%	1868
2022 Q2	–	Hold	0	–	–	–	1602

Other funds holding CTKB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Man Group's CTKB Position: Q3 2023 in Review

Man Group sold out of Cytek Biosciences (CTKB) in Q3 2023, closing a stake of 13,700 shares — an estimated $110K sold.

Man Group first reported a position in CTKB in Q2 2023 and held it in 1 quarter. The position peaked at $117K in Q2 2023. 106 funds tracked by Wall St. Rank hold CTKB as of Q3 2023.

Man Group reported no remaining Cytek Biosciences position as of Q3 2023 after selling out during the quarter.
Man Group sold 13,700 Cytek Biosciences shares in Q3 2023, an estimated $110K.
Man Group first reported a position in Cytek Biosciences in Q2 2023 and held it in 1 quarter.
Man Group's Cytek Biosciences position peaked at $117K in Q2 2023.
106 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2023.

Based on Man Group's 13F filing for Q3 2023, filed 14 Nov 2023.